Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 674

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 674
---
──────────────────────────────────────────────────────────────────────────
Oncology/ Other
Immunology Ventures Total
(in US$ ’ 000)
Invoiced Goods - Marketed Products 57,057 - 57,057
 - Distribution - 262,565 262,565
Services - Commercialization of Marketed Products 41,275 - 41,275
 - Research and development 507 - 507
License & Collaborations - Services 23,741 - 23,741
 - Royalties 26,310 - 26,310
 - Licensing 14,954 - 14,954
163,844 262,565 426,409
Third parties 163,337 257,272 420,609
Related parties (Note 23(i)) 507 5,293 5,800
163,844 262,565 426,409

F-36

Table of Contents

The following table presents liability balances from contracts with customers:
December 31,
2024 2023
─────────────────────────────────────────────────────────────────────────────────────────
(in US$ ’ 000)
Deferred revenue
Current - Oncology/Immunology segment (note (a)) 50,007 57,566
Current - Other Ventures segment (note (b)) 64 73
50,071 57,639
Non-current - Oncology/Immunology segment (note (a)) 48,432 69,480
Total deferred revenue (note (c) and (d)) 98,503 127,119
Notes:
(a) Oncology/Immunology segment deferred revenue relates to unamortized upfront and milestone payments, invoiced amounts for royalties where the customer has not yet completed the in-market sale an...
(b) Other Ventures segment deferred revenue relates to payments in advance from customers for goods that have not been transferred and services that have not been rendered to the customer as at the...
(c) Estimated deferred revenue to be recognized over time as from the date indicated is as follows:
December 31,
2024 2023
──────────────────────────────────────────────────────────
(in US$ ’ 000)
Not later than 1 year 50,071 57,639
Between 1 to 2 years 39,288 32,797
Between 2 to 3 years 4,084 30,918
Between 3 to 4 years 1,095 844